What is MIMs?
Founded in 2016 and headquartered in Quebec, Canada, MIMs operates at the vanguard of digital health and systems biology. The company specializes in providing pharmaceutical organizations with sophisticated augmented intelligence systems that facilitate accurate biological simulations. By integrating complex data sets into actionable insights, MIMs enables scientists to streamline the drug discovery process, significantly reducing the time and cost associated with bringing personalized therapies to market. Its market position is defined by its ability to bridge the gap between high-level computational biology and practical, easy-to-implement enterprise software solutions.
How much funding has MIMs raised?
MIMs has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2021): $5M with participation from Anges Québec, Medteq, Anges Québec Capital, Real Ventures, Desjardins Capital, and StandUp Ventures
Key Investors in MIMs
Real Ventures
Real Ventures serves mission-driven entrepreneurs and nurtures the communities in which they thrive, backing visionary founders building innovative tech companies with large-scale positive impacts.
StandUp Ventures
Stand Up Ventures is a stage venture capital fund focused on investing in high growth ventures, established in 2017 and based in Toronto, Ontario.
Desjardins Capital
A prominent investment firm providing long-term capital and strategic support to businesses across various sectors to foster sustainable economic growth.
What's next for MIMs?
Following this major enterprise-level funding, MIMs is expected to prioritize the expansion of its technical infrastructure and the scaling of its commercial operations. The strategic roadmap likely includes deepening its footprint within the global pharmaceutical ecosystem and enhancing the predictive capabilities of its core simulation engine. As the demand for precision medicine continues to rise, the company is poised to leverage its recent capital to solidify its competitive advantage, potentially exploring new therapeutic areas and expanding its reach into international markets. The focus remains on maintaining its trajectory as a critical partner for researchers seeking to optimize the development of next-generation medical treatments.
See full MIMs company page
